



国内版

国际版

Prognostic factors for overall survival in prostate cancer patients with differ



网页

图片

视频

学术

词典

地图

检测到您输入了英文，试试切换到国际版？搜英文结果更丰富更准确



803,000 条结果 时间不限

Updated Prognostic Model for Predicting Overall ... 翻译此页

Cited by: 267

Author: Susan Halabi, Chen-Yen Lin, W. Kevin Kel...

Publish Year: 2014

位置: 8600 Rockville Pike, Bethesda, MD

2014-3-1 · Prognostic models for overall survival (OS) for patients with metastatic castration-resistant prostate cancer (mCRPC) are dated and do not reflect significant advances in treatment options available for these patients. This work developed and validated an updated prognostic model to predict OS in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927736>

prognostic index model for predicting overall survival ... 翻译此页

Cited by: 75

Author: K. N. Chi, T. Kheoh, C. J. Ryan, A. Molina,...

Publish Year: 2016

2015-12-18 · Few prognostic models for overall survival (OS) are available for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with recently approved agents. We developed a prognostic index model using readily available clinical and laboratory factors from a phase III trial of abiraterone acetate (hereafter abiraterone) in ...

<https://academic.oup.com/annonc/article/27/3/454/2196309>

Prognostic Model Predicting Metastatic Castration ... 翻译此页

位置: 8600 Rockville Pike, Bethesda, MD

2013-11-20 · Several prognostic models for overall survival (OS) have been developed and validated in men with metastatic castration-resistant prostate cancer (mCRPC) who receive first-line chemotherapy. We sought to develop and validate a prognostic model to predict OS in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833929>

Prognostic factors of overall survival in patients with ...

rate in this group of patients as well as to identify prognostic factors of OS which could be helpful in choosing the best possible approach for every patient. Key words: castration-resistant prostate cancer, docetaxel, abiraterone acetate, cabazitaxel, overall survival, prognostic factors, alkaline

<https://oncourology.abvpress.ru/oncur/article/viewFile/457/482>



10

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 52169

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: A study of 1358 patients

Cui PF *et al.* Prognostic factors for PCa patients with VM

Peng-Fei Cui, Xiao-Feng Cong, Feng Gao, Jia-Xin Yin, Zi-Ru Niu, Song-Chen Zhao, Zi-Ling Liu

Match Overview



1	Internet 39 words crawled on 12-Jul-2019 www.jcancer.org	1%
2	Internet 25 words crawled on 31-May-2019 onlinelibrary.wiley.com	1%
3	Internet 19 words crawled on 24-Jul-2019 tcr.amegroups.com	<1%
4	Internet 19 words crawled on 05-Sep-2019 academic.oup.com	<1%
5	Internet 18 words crawled on 01-Sep-2019 www.spandidos-publications.com	<1%
6	Crossref 17 words J J Tosoian, R Alam, C Gergis, A Narang, N Radwan, S R obertson, T McNutt, A E Ross, D Y Song, T L DeWeese,	<1%
7	Internet 17 words crawled on 06-Feb-2010 www.europeanurology.com	<1%
8	Crossref 16 words Jongchan Kim, Jee Soo Park, Won Sik Ham. "The role of metastasis-directed therapy and local therapy of the pri ...	<1%
9	Internet 14 words crawled on 01-Sep-2019 publishing.rcseng.ac.uk	<1%
10	Internet 14 words crawled on 05-Oct-2019 f6publishing.blob.core.windows.net	<1%
11	Internet 13 words crawled on 10-Jan-2017	<1%



29,700 Results

Any time ▾

Prognostic factors and risk stratification in patients ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802623>

Mar 22, 2016 · We previously reported that **visceral metastases**, including lung, liver and lymph nodes and excluding bone, and pretreatment anemia (hemoglobin < 11.3 g/dL) were two independent **factors** predicting **overall survival** in **patients** who received docetaxel chemotherapy for **prostate cancer**. In a previous **study**, we collected the data from not only our ...

Cited by: 6

Author: Shimpei Yamashita, Yasuo Kohjimoto, Ta...

Publish Year: 2016

Impact of the Site of Metastases on Survival in Patients ...

[https://www.europeanurology.com/article/S0302-2838\(14\)00672-1/fulltext](https://www.europeanurology.com/article/S0302-2838(14)00672-1/fulltext)

After stratifying patients according to the metastatic site, respective median overall survival and CSM-free survival were 43 mo and 61 mo for men with **LN metastases**, 24 mo and 32 mo for men with **bone metastases**, 16 mo and 26 mo for men with **visceral metastases**, and 14 mo and 19 mo for men with **visceral plus bone metastases** ($p < 0.001$) (Fig. 3 a and 3b).

Cited by: 78

Author: Giorgio Gandaglia, Giorgio Gandaglia, Pie...

Publish Year: 2015

Predictors of survival in prostate cancer patients with ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494633>

Feb 12, 2015 · Prostate-specific antigen (PSA) is a surrogate marker of disease progression; however, its predictive ability in the extreme ranges is unknown. We determined the predictors of **survival** in **patients** with bone metastatic **prostate cancer** (BMPCa) ...

Cited by: 15

Author: Kyo Chul Koo, Sang Un Park, Ki Hong Ki...

Publish Year: 2015

Visceral Metastases and Prostate Cancer Treatment: 'Die ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882930>

The Biology of Bone and **Visceral Metastases** in Prostate Cancer. Despite the high prevalence of **visceral metastases** in men with mCRPC, and the well-documented association of **visceral** disease with poor outcomes (Figure 1),[] few studies have examined cell-intrinsic, tumor microenvironment, or systemic **factors** that might contribute to the differences between **visceral** and bone disease in men with ...

Cited by: 11

Author: Charles G. Drake